🚀 VC round data is live in beta, check it out!
Curiox Biosystems Valuation Multiples
Discover revenue and EBITDA valuation multiples for Curiox Biosystems and similar public comparables like Shanghai Haohai, Pulse Biosciences, Savaria, AdaptHealth and more.
Curiox Biosystems Overview
About Curiox Biosystems
Curiox Biosystems Co Ltd is Korean Based company which brings together decades of scientific and engineering expertise in surface chemistry and life science instrumentation with the goal of overcoming critical challenges that slow the pace of life science research. The company has introduced Laminar Wash technology, which automates cell processing and enables highly reproducible and high-throughput cell analysis. The company offers various products such as LAMINAR WASH AUTO 1000 SYSTEM, Curiox Laminar Wash HT2000 System and Laminar Wash MINI System.
Founded
2018
HQ
Employees
N/A
Website
Financials (LTM)
EV
$1B
Curiox Biosystems Financials
Curiox Biosystems reported last 12-month revenue of $3M.
In the same LTM period, Curiox Biosystems generated had net loss of ($12M).
Revenue (LTM)
Curiox Biosystems P&L
In the most recent fiscal year, Curiox Biosystems reported revenue of $3M and EBITDA of ($15M).
Curiox Biosystems expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $1M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 41% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($15M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (452%) | XXX | XXX | XXX |
| EBIT Margin | (241%) | XXX | (232%) | XXX | XXX | XXX |
| Net Profit | ($12M) | XXX | ($12M) | XXX | XXX | XXX |
| Net Margin | (351%) | XXX | (338%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Curiox Biosystems Stock Performance
Curiox Biosystems has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Curiox Biosystems' stock price is $74.32.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -0.0% | XXX | XXX | XXX | $-0.68 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCuriox Biosystems Valuation Multiples
Curiox Biosystems trades at 381.6x EV/Revenue multiple, and (81.4x) EV/EBITDA.
EV / Revenue (LTM)
Curiox Biosystems Financial Valuation Multiples
As of April 1, 2026, Curiox Biosystems has market cap of $1B and EV of $1B.
Equity research analysts estimate Curiox Biosystems' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Curiox Biosystems has a P/E ratio of (109.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | 381.6x | XXX | 367.9x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (81.4x) | XXX | XXX | XXX |
| EV/EBIT | (158.3x) | XXX | (158.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 887.5x | XXX | XXX | XXX |
| P/E | (109.8x) | XXX | (109.8x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (168.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Curiox Biosystems Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Curiox Biosystems Margins & Growth Rates
Curiox Biosystems' revenue in the last fiscal year grew by 12%.
Curiox Biosystems Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 12% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (452%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 393% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 22% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 51% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 280% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Curiox Biosystems Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Shanghai Haohai | XXX | XXX | XXX | XXX | XXX | XXX |
| Pulse Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Savaria | XXX | XXX | XXX | XXX | XXX | XXX |
| AdaptHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| El.En. Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curiox Biosystems M&A Activity
Curiox Biosystems acquired XXX companies to date.
Last acquisition by Curiox Biosystems was on XXXXXXXX, XXXXX. Curiox Biosystems acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Curiox Biosystems
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCuriox Biosystems Investment Activity
Curiox Biosystems invested in XXX companies to date.
Curiox Biosystems made its latest investment on XXXXXXXX, XXXXX. Curiox Biosystems invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Curiox Biosystems
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Curiox Biosystems
| When was Curiox Biosystems founded? | Curiox Biosystems was founded in 2018. |
| Where is Curiox Biosystems headquartered? | Curiox Biosystems is headquartered in South Korea. |
| Is Curiox Biosystems publicly listed? | Yes, Curiox Biosystems is a public company listed on Korea Exchange. |
| What is the stock symbol of Curiox Biosystems? | Curiox Biosystems trades under 445680 ticker. |
| When did Curiox Biosystems go public? | Curiox Biosystems went public in 2023. |
| Who are competitors of Curiox Biosystems? | Curiox Biosystems main competitors are Shanghai Haohai, Pulse Biosciences, Savaria, AdaptHealth. |
| What is the current market cap of Curiox Biosystems? | Curiox Biosystems' current market cap is $1B. |
| What is the current revenue of Curiox Biosystems? | Curiox Biosystems' last 12 months revenue is $3M. |
| What is the current EV/Revenue multiple of Curiox Biosystems? | Current revenue multiple of Curiox Biosystems is 381.6x. |
| Is Curiox Biosystems profitable? | No, Curiox Biosystems is not profitable. |
| What is the current net income of Curiox Biosystems? | Curiox Biosystems' last 12 months net income is ($12M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.